Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $19.16
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Sep 24, 26 |
| Truist Securities |
| maintain |
| Buy |
| Buy |
| Sep 15, 26 | B of A Securities | maintain | Neutral | Neutral |
| Sep 15, 26 | Truist Securities | maintain | Buy | Buy |
| Sep 15, 26 | Baird | maintain | Neutral | Neutral |
| Sep 14, 26 | Leerink Partners | maintain | Outperform | Outperform |
| Jul 15, 26 | Goldman Sachs | maintain | Buy | Buy |
| Jul 13, 26 | Truist Securities | maintain | Buy | Buy |
| May 27, 26 | Goldman Sachs | maintain | Buy | Buy |
| May 18, 26 | B of A Securities | maintain | Neutral | Neutral |
436 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 54.47 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 85.80 | Oscillator | Sell |
| Williams %R (14) | -11.80 | Oscillator | Sell |
| MACD (12, 26, 9) | -0.26 (Hist 0.14) | Oscillator | Buy |
| Average Directional Index (14) | 18.42 (+DI 22.9 / -DI 18.8) | Trend | Neutral |
| EMA 20 | 18.39 | MA | Strong Buy |
| SMA 20 | 18.25 | MA | Strong Buy |
| EMA 50 | 18.33 | MA | Strong Buy |
| SMA 50 | 19.10 | MA | Buy |
| SMA 200 | 14.87 | MA | Strong Buy |
TTM vs. 5-year historical average (annual ratios)
| Metric | BBNX | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -11.4x | -18.5x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -9.5x | EPS est. -2.02 | Discount |
| Price / Book | 3.3x | 7.2x | Discount |
| Price / Sales | 7.2x | 1442.6x | Discount |
| EV / EBITDA | -11.5x | -18.9x | Discount |
| Return on equity | -26.3% | — | Weak |
| Gross margin | 58.3% | 65.8% | In line |
| Debt / Equity | 0.03 | 0.04 | Conservative |
| Piotroski / Altman Z | 2/9 | Z 12.91 | Safe zone |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 14, 26 | Hopman Mark | officer: Chief Commercial Officer | S-Sale | 775 @ $17.35 | $13.45K |
| Oct 1, 26 | Hopman Mark | officer: Chief Commercial Officer | S-Sale | 370 @ $18.96 | $7.02K |
| Sep 22, 26 | Jones Christy | director | S-Sale | 6,430 @ $23.00 | $147.9K |
| Sep 9, 26 | Hopman Mark | officer: Chief Commercial Officer | S-Sale | 35,994 @ $18.46 | $664.6K |
| Sep 16, 26 | Hopman Mark | officer: Chief Commercial Officer | S-Sale | 30,779 @ $20.13 | $619.6K |
| Sep 16, 26 | Mensinger Mike | officer: Chief Product Officer | S-Sale | 2,650 @ $22.00 | $58.30K |
| Sep 14, 26 | Hopman Mark | officer: Chief Commercial Officer | S-Sale | 775 @ $15.52 | $12.03K |
| Sep 9, 26 | Hopman Mark | officer: Chief Commercial Officer | S-Sale | 36,870 @ $18.46 | $680.7K |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 16, 2026 | 2026-10-16 16:10:49 | View |
| SC 13G | Oct 7, 2026 | 2026-10-07 14:56:44 | View |
| 4 | Oct 5, 2026 | 2026-10-05 17:11:13 | View |
| 4 | Sep 23, 2026 | 2026-09-23 17:40:52 | View |
| 4/A | Sep 18, 2026 | 2026-09-18 19:51:40 | View |
| 4 | Sep 17, 2026 | 2026-09-17 16:15:14 | View |
| 4 | Sep 17, 2026 | 2026-09-17 16:15:13 | View |
| 8-K | Sep 17, 2026 | 2026-09-16 18:24:10 | View |
| 424B5 | Sep 17, 2026 | 2026-09-16 18:21:57 | View |
| FWP | Sep 16, 2026 | 2026-09-15 20:15:51 | View |
Proxy statement (DEF 14A) disclosures
Stock news · updated daily
NEW YORK and NEW ORLEANS , Oct. 23, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NasdaqGM: BBNX) of a class action securities lawsuit.
New York, New York--(Newsfile Corp. - October 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Beta Bionics, Inc. (NASDAQ: BBNX) between July 30, 2025 and February 24, 2026, both dates inclusive (the "Class Period"), of the important November 3, 2026 lead plaintiff deadline. SO WHAT: If you purchased Beta Bionics common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
New York, New York--(Newsfile Corp. - October 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Beta Bionics and have suffered losses, you may CLICK HERE to contact us.
San Diego, California--(Newsfile Corp. - October 23, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Beta Bionics, Inc. (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the "Class Period"). Beta Bionics is a commercial-stage medical device company that offers an automated insulin delivery system for the treatment of diabetes, known as the iLet Bionic Pancreas insulin pump ("iLet").
SAN FRANCISCO, Oct. 23, 2026 /PRNewswire/ -- Hagens Berman reminds investors in Beta Bionics, Inc. (NASDAQ: BBNX) of the pending securities class action lawsuit and upcoming November 3, 2026 lead plaintiff deadline under the Private Securities Litigation Reform Act (PSLRA). Investors who suffered substantial losses purchasing Beta Bionics stock during the Class Period between July 30, 2025 and February 24, 2026, inclusive, are encouraged to submit your losses now to Hagens Berman to discuss their legal options.
NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you are an investor in Beta Bionics and have suffered losses, you may CLICK HERE to contact us.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Beta Bionics To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Beta Bionics between July 30, 2025 and February 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - October 23, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX) and reminds investors of the November 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ:BBNX) and certain of the company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in Beta Bionics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 29, 2026 | -0.58 | -0.53 | Beat 8.8% | $32.01M |
| Apr 21, 2026 | -0.53 | -0.49 | Beat 7.5% | $27.63M |
| Feb 17, 2026 | -0.42 | -0.30 | Beat 28.6% | $32.12M |
| Oct 28, 2025 | -0.45 | -0.33 | Beat 26.7% | $27.25M |
| Jul 29, 2025 | -0.51 | -0.39 | Beat 23.5% | $23.24M |
| May 6, 2025 | -0.51 | -0.52 | Miss -2.0% | $17.64M |